The study, consisting of 194 participants followed over two years, found that daily use of Exenatide did not provide any significant improvement for Parkinsons symptoms compared to the placebo
Personalized multimorbidity management for patients with type 2 diabetes using reinforcement learning of electronic health records
As of early 2026, no peer-reviewed human clinical trials for BPC-157 have been published
Common adverse effects include: Gastrointestinal symptoms nausea, vomiting, diarrhoea, constipation, and abdominal pain (affecting up to 40% of users) Reduced appetite and weight loss Injection site reactions redness, itching, or discomfort Hypoglycaemia particularly when used alongside insulin or sulfonylureas More serious but rare adverse effects include pancreatitis (inflammation of the pancreas) and gallbladder disease
GHK-Cu may additionally promote collagen synthesis, particularly at the interface between tendon cells and bone cells
How Do Compounded GLP-1 Medications Differ from Commercial Options